1. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). (16th September 2015) Authors: Long, E.; Ilie, M.; Lassalle, S.; Butori, C.; Poissonnet, G.; Washetine, K.; Mouroux, J.; Lespinet, V.; Lacour, J.P.; Taly, V.; Laurent‐Puig, P.; Bahadoran, P.; Hofman, V.; Hofman, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 12(2015:Dec.) Page Start: 2436 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Association of combined PD‐L1 expression and tumour‐infiltrating lymphocyte features with survival and treatment outcomes in patients with metastatic melanoma. (24th November 2019) Authors: Bence, C.; Hofman, V.; Chamorey, E.; Long‐Mira, E.; Lassalle, S.; Albertini, A.F.; Liolios, I.; Zahaf, K.; Picard, A.; Montaudié, H.; Lacour, J.P.; Passeron, T.; Andea, A.A.; Ilie, M.; Hofman, P. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 34:Number 5(2020) Page Start: 984 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗